Study Enrollment

Your details will not be published or shared.

Clinical Trial

A011106; ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: a phase III study

Anastrozole is an oral medication taken daily that lowers estrogen in postmenopausal women. It is a standard of care to take anastrozole before surgery to shring estrogen receptor positive breast cancer. The purpose of this study is to determine whether neoadjuvant endocrine therapy with fulvestrant or the combination of anastrozole and fulvestrant, is better than anastrozole when given before surgery to shrink the cancer and stop it from growing.

Eligibility Criteria

  • 18 years of age or older Must have confirmed Breast Cancer ECOG performance of 0 - 2

Contact Information

    Kelly Adams

    (706) 446-5177